[The use of neurotropic therapy in young patients with postcovid syndrome].

Ivonina NA, Petrov KB

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2022Cited by 2 (Europe PMC)

PMID35394732DOI10.17116/jnevro2022122031126PepBankPUB-35394732

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

01HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In young post-COVID patients, general asthenia decreased significantly after combined Cortexin and Recognan therapy.
In plain wordsYoung post-COVID patients had significantly less general asthenia after combined Cortexin and Recognan therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseGeneral asthenia
Study
n = 87
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
After the complex treatment, there was a significant decrease in the indicators of common, physical, mental asthenia, as well as an increase in motivational activity, there was a decrease in situational anxiety, and to a lesser extent personal anxiety.
2 context sentences(design, population, supporting numbers)
Summary · context
Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist.
Summary · context
All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3539473201
02HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In young post-COVID patients, physical asthenia decreased significantly after combined Cortexin and Recognan therapy.
In plain wordsYoung post-COVID patients had significantly less physical asthenia after combined Cortexin and Recognan therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreasePhysical asthenia
Study
n = 87
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
After the complex treatment, there was a significant decrease in the indicators of common, physical, mental asthenia, as well as an increase in motivational activity, there was a decrease in situational anxiety, and to a lesser extent personal anxiety.
2 context sentences(design, population, supporting numbers)
Summary · context
Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist.
Summary · context
All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3539473202
03HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In young post-COVID patients, mental asthenia decreased significantly after combined Cortexin and Recognan therapy.
In plain wordsYoung post-COVID patients had significantly less mental asthenia after combined Cortexin and Recognan therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseMental asthenia
Study
n = 87
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
After the complex treatment, there was a significant decrease in the indicators of common, physical, mental asthenia, as well as an increase in motivational activity, there was a decrease in situational anxiety, and to a lesser extent personal anxiety.
2 context sentences(design, population, supporting numbers)
Summary · context
Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist.
Summary · context
All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3539473203
04HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In young post-COVID patients, motivational activity increased after combined Cortexin and Recognan therapy.
In plain wordsYoung post-COVID patients showed greater motivational activity after combined Cortexin and Recognan therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseMotivational activity
Study
n = 87
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
After the complex treatment, there was a significant decrease in the indicators of common, physical, mental asthenia, as well as an increase in motivational activity, there was a decrease in situational anxiety, and to a lesser extent personal anxiety.
2 context sentences(design, population, supporting numbers)
Summary · context
Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist.
Summary · context
All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3539473204
05HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In young post-COVID patients, situational anxiety decreased after combined Cortexin and Recognan therapy.
In plain wordsYoung post-COVID patients had less situational anxiety after combined Cortexin and Recognan therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseSituational anxiety
Study
n = 87
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
After the complex treatment, there was a significant decrease in the indicators of common, physical, mental asthenia, as well as an increase in motivational activity, there was a decrease in situational anxiety, and to a lesser extent personal anxiety.
2 context sentences(design, population, supporting numbers)
Summary · context
Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist.
Summary · context
All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3539473205
06HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In young post-COVID patients, personal anxiety decreased less than situational anxiety after combined Cortexin and Recognan therapy.
In plain wordsYoung post-COVID patients had less personal anxiety after Cortexin plus Recognan therapy, with a smaller decrease than for situational anxiety.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreasePersonal anxiety
Study
n = 87
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
After the complex treatment, there was a significant decrease in the indicators of common, physical, mental asthenia, as well as an increase in motivational activity, there was a decrease in situational anxiety, and to a lesser extent personal anxiety.
2 context sentences(design, population, supporting numbers)
Summary · context
Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist.
Summary · context
All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3539473206
07HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In young post-COVID patients, MMSE performance improved after combined Cortexin and Recognan therapy.
In plain wordsYoung post-COVID patients had better MMSE performance after combined Cortexin and Recognan therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseMMSE performance
Study
n = 87
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
According to cognitive tests, there was an improvement in indicators on the MMSE scale, direct reproduction of the 5-word test, significant changes in the evaluation of work efficiency when performing the Schulte test.
2 context sentences(design, population, supporting numbers)
Summary · context
Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist.
Summary · context
All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3539473207
08HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In young post-COVID patients, direct reproduction on the 5-word test improved after combined Cortexin and Recognan therapy.
In plain wordsYoung post-COVID patients recalled words better on the 5-word test after combined Cortexin and Recognan therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseDirect reproduction on 5-word test
Study
n = 87
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
According to cognitive tests, there was an improvement in indicators on the MMSE scale, direct reproduction of the 5-word test, significant changes in the evaluation of work efficiency when performing the Schulte test.
2 context sentences(design, population, supporting numbers)
Summary · context
Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist.
Summary · context
All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3539473208
09HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome
In young post-COVID patients, Schulte test work efficiency changed significantly after combined Cortexin and Recognan therapy.
In plain wordsYoung post-COVID patients showed significant changes in Schulte test work efficiency after combined Cortexin and Recognan therapy.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
Direction not reportedSchulte test work efficiency
Study
n = 87
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
According to cognitive tests, there was an improvement in indicators on the MMSE scale, direct reproduction of the 5-word test, significant changes in the evaluation of work efficiency when performing the Schulte test.
2 context sentences(design, population, supporting numbers)
Summary · context
Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist.
Summary · context
All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3539473209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.